Skip to main content
Regulatory Intelligence

Compliance Updates & Regulatory News

Recent items GuardWell's regulatory intelligence engine flagged as relevant to small medical practices, from federal sources such as Federal Register documents by HHS, CMS, OSHA, DEA, FDA, and other agencies, alongside milestone changes selected by our team.

Last refreshed November 18, 2026. This page changes only when we publish the site, so check each item's source for its current status.

November 2026

November 16, 2026CMS

Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of the Extension and Modification of the Nationwide Temporary Moratorium on Enrollment of Home Health Agencies (HHAs)

This notice announces the extension and modification of the nationwide temporary moratorium on the enrollment of new Medicare Home Health Agencies.

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services
November 13, 2026CMS

Agency Information Collection Activities: Submission for OMB Review; Comment Request

The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Reg…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services
November 12, 2026HIPAACMSMACRA

ONC and CMS Launch Industry Initiative Advancing Electronic Prior Authorization Testing 

When a patient is waiting for care, every handoff in the prior authorization process matters. […] The post ONC and CMS Launch Industry Initiative Advancing Electronic Prior Authorization Testing  appeared first on ONC Blog.

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: HealthIT.gov Buzz Blog
November 12, 2026DEA

Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV

On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DE…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Drug Enforcement Administration
November 12, 2026CLIA

Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product

The Food and Drug Administration (FDA) is proposing to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER, and SHF), which are postam…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services
November 10, 2026DEA

Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027

The Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Drug Enforcement Administration
November 10, 2026DEA

Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)

The Drug Enforcement Administration (DEA) is adjusting the 2026 aggregate production quota for the schedule II controlled substances d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). In making this determination, DEA has considered the fac…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Drug Enforcement Administration
November 10, 2026CMSMACRA

Medicare and Medicaid Programs; Cutting Administrative Requirements for Excellence in Patient Care

This proposed rule would reform Medicare and Medicaid regulations deemed obsolete or excessively burdensome on healthcare providers and suppliers, with the objective of reducing costs, enhancing flexibility in delivering innovative care, and streamlining existing regulations. Th…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Centers for Medicare and Medicaid Services
November 10, 2026CLIA

Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency; Guidance for Industry and Food and Drug Administration Staff; Availability

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency." The guidance describes general recommendations for the v…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services
November 9, 2026CMS

Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program

This rule finalizes and codifies the Medicare Drug Price Negotiation Program ("Negotiation Program") and establishes certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program ("Part D Program") as required by the Inflation Reduction Act…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services
November 9, 2026CMSCLIAMACRA

Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program

This final rule addresses: changes to the physician fee schedule (PFS); other changes to Medicare Part B payment policies to ensure that payment systems are updated to reflect changes in medical practice, relative value of services, and changes in the statute; codification of es…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services
November 6, 2026CMSALLERGY

Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Cl

This final rule with comment period revises the Medicare Hospital Outpatient Prospective Payment System (OPPS) and the Medicare Ambulatory Surgical Center (ASC) payment system for calendar year 2027 based on our continuing experience with these systems. We also describe the chan…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services
November 5, 2026CLIA

Medical Devices; Hematology and Pathology Devices; Classification of the Digital Cervical Cytology Slide Imaging System With Artificial Intelligence Algorithm

The Food and Drug Administration (FDA) is classifying the digital cervical cytology slide imaging system with artificial intelligence algorithm into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of t…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services
November 4, 2026DEA

Technical Amendment to the Regulation Regarding Amendments to Applications

This final rule updates a Drug Enforcement Administration regulation to clarify that the provision regarding amendments to and withdrawal of registration applications also applies to applications for registration renewal. This action makes no substantive changes to this regulati…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Drug Enforcement Administration
November 3, 2026HIPAACMS

Nondiscrimination on the Basis of Disability in Programs or Activities Receiving Federal Financial Assistance

The Department of Health and Human Services (HHS or Department) issues this rule to revise the regulation implementing section 504 of the Rehabilitation Act of 1973 (section 504) as it applies to recipients of HHS funding (entitled "Nondiscrimination on the Basis of Disability i…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services
November 2, 2026CMS

Emergency Clearance: Public Information Collection Requirements Submitted to the Office of Management and Budget (OMB)

The Centers for Medicare & Medicaid Services (CMS) is requesting that an information collection request revision for the Review Choice Demonstration or Home Health Services (CMS-10599/0938- 1311) processed under the emergency clearance process associated with the implementing re…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services

October 2026

October 30, 2026DEA

Schedules of Controlled Substances: Placement of Centanafadine in Schedule III

On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder in adults and pediatric patients aged 6 years and older, weighing at least 20 kg. The…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Drug Enforcement Administration
October 30, 2026CMS

Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury (AKI) Dialysis Payment, and ESRD Quality Incentive Program

This final rule updates and revises the End-Stage Renal Disease (ESRD) Prospective Payment System for calendar year 2027. This rule also includes updates to the payment rate for renal dialysis services furnished by an ESRD facility to individuals with acute kidney injury. In add…

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services
October 29, 2026CLIA

Mandatory Guidelines for Federal Workplace Drug Testing Programs Using Oral Fluid (OFMG)

The Department of Health and Human Services ("HHS" or "Department") is proposing to revise the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid (OFMG) published on October 12, 2023.

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services
October 29, 2026CLIA

Mandatory Guidelines for Federal Workplace Drug Testing Programs Using Urine (UrMG)

The Department of Health and Human Services ("HHS" or "Department") is proposing to revise the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine (UrMG), published in the Federal Register on October 12, 2023).

Sign in to GuardWell to see how this impacts your specific practice — the in-app analyzer scores per-framework relevance and suggests concrete actions.
Source: Federal Register — Department of Health and Human Services

February 2026

February 16, 2026HIPAA

42 CFR Part 2 Aligns with HIPAA — Substance Use Disorder Records

The final rule aligning 42 CFR Part 2 with HIPAA took effect February 16, 2026. Substance use disorder (SUD) treatment records can now be disclosed under the same framework as other protected health information, reducing the separate-consent burden for providers while maintaining patient protections against use in legal proceedings.

What this means for your practice

Practices that handle SUD records should update their Notice of Privacy Practices and train staff on the streamlined disclosure rules.

Source: SAMHSA / HHS

November 2025

November 5, 2025CMS

CMS Holds the MIPS Performance Threshold at 75 Points Through 2028

CMS's CY 2026 Medicare Physician Fee Schedule final rule (CMS-1832-F, published November 5, 2025) keeps the MIPS performance threshold at 75 points for the 2026, 2027, and 2028 performance periods. The rule also adds six MIPS Value Pathways (MVPs): Diagnostic Radiology, Interventional Radiology, Neuropsychology, Pathology, Podiatry, and Vascular Surgery.

What this means for your practice

If you report traditional MIPS, the target is still 75 points. CMS's CY 2027 Physician Fee Schedule final rule keeps traditional MIPS available through the 2030 performance period, so there is no need to rush into an MVP; consider one if it fits your specialty.

Source: Federal Register (CMS-1832-F)

June 2025

June 18, 2025HIPAA

Court Vacates the 2024 HIPAA Reproductive Health Privacy Rule

On June 18, 2025, a federal court in Texas (Purl v. HHS, N.D. Tex.) vacated nationwide the 2024 HIPAA Privacy Rule changes that added special protections for reproductive health information, including the attestation requirement for certain disclosures. HHS did not appeal. An appeal by the cities of Columbus and Madison and Doctors for America, who had sought to intervene to defend the rule, was dismissed at their own request on September 10, 2025, so the vacatur stands. The court left in place the rule's Notice of Privacy Practices changes tied to 42 CFR Part 2, except three paragraphs that described the vacated protections (45 CFR 164.520(b)(1)(ii)(F), (G), and (H)).

What this means for your practice

Do not rely on the 2024 reproductive health rule, and do not add its attestation language to your Notice of Privacy Practices. Keep the Part 2 substance use disorder NPP language, which survived. Check your state's law, since some states have their own reproductive health privacy requirements.

Source: U.S. District Court, Northern District of Texas

January 2025

January 15, 2025OIG

OIG Releases 2025 Work Plan: Healthcare Fraud Priorities

The HHS Office of Inspector General published its 2025 Work Plan highlighting enforcement priorities for healthcare providers — telehealth billing oversight, Medicare Advantage risk adjustment audits, opioid prescribing patterns, and laboratory test utilization reviews.

What this means for your practice

Review your billing practices for telehealth services and ensure documentation supports medical necessity. Audit high-risk CPT codes flagged in the plan.

Source: HHS Office of Inspector General
January 6, 2025HIPAA

HHS Proposes Major HIPAA Security Rule Overhaul

HHS published a Notice of Proposed Rulemaking to modernize the HIPAA Security Rule for the first time since 2013. Key proposals include mandatory encryption of ePHI at rest and in transit, required multi-factor authentication, annual compliance audits, and more prescriptive technical safeguard standards. The comment period has closed, but the rule is still only a proposal: HHS has not issued a final rule. HHS's regulatory agenda lists it as a long-term action with a final-rule target of July 2027, which is an estimate, not a deadline.

What this means for your practice

Start preparing now: assess current encryption practices, evaluate MFA readiness, and review your Security Risk Analysis process.

Source: HHS Office for Civil Rights

Keep up with compliance changes

Inside GuardWell, the regulatory intelligence engine checks federal sources and alerts your practice to the changes that affect it, with a plain-English summary and suggested next steps.

See how it works

All-in-one healthcare compliance, finally simple

HIPAA, OSHA, OIG, DEA, MACRA, allergen safety, state law — purpose-built for small and mid-size medical practices. Start your 7-day free trial today.

$125/mo ($100/mo billed annually) · 7-day free trial · Cancel anytime

GuardWell

Healthcare Compliance Assistant

Hi! I'm GuardWell's AI sales assistant (automated, not a human).

I can answer questions about our healthcare compliance platform, pricing, and features. How can I help?

Powered by GuardWell AI